XML 27 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues [Abstract]      
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 832,010 $ 10,262,268 $ 1,774,758
Operating expenses:      
Research and development 86,676,563 187,650,503 249,240,324
General and administrative 47,582,104 90,185,285 53,752,353
Impairment of goodwill 10,513,371 0 0
Total operating expenses 144,772,038 277,835,788 302,992,677
Loss from operations (143,940,028) (267,573,520) (301,217,919)
Other income (expense):      
Interest income 8,133,290 4,782,030 3,363,080
Interest expense (1,222,789) (1,253,952) (1,936,447)
Gain (loss) on investment in affiliated entity 773,145 (1,899,654) (553,570)
Net unrealized gain (loss) on available-for-sale equity securities 5,850,626 (7,846,172) (3,222,838)
Other (expense) income, net (4,711,596) (3,861,584) 343,371
Net loss before share in net loss of Geneos (135,117,352) (277,652,852) (303,224,323)
Share in net loss of Geneos 0 (2,165,213) (434,387)
Net loss $ (135,117,352) $ (279,818,065) $ (303,658,710)
Net loss per share      
Basic (in dollars per share) [1] $ (6.09) $ (14.07) $ (17.45)
Diluted (in dollars per share) [1] $ (6.09) $ (14.07) $ (17.45)
Weighted average number of common shares outstanding      
Basic (in shares) [1] 22,173,662 19,885,182 17,402,483
Diluted (in shares) [1] 22,173,662 19,885,182 17,402,483
[1]
(1) Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented.